Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections

被引：0
|
作者：
Rieko Nishimura
Nami Okamoto
Masakazu Satou
Kenta Kojima
Shinichi Tanaka
Natsumi Yamashita
机构：
[1] National Hospital Organization Shikoku Cancer Center,Department of Clinical Laboratory
[2] National Hospital Organization Shikoku Cancer Center,Division of Clinical Biostatistics, Section of Cancer Prevention and Epidemiology, Clinical Research Center
来源：
Breast Cancer | 2016年 / 23卷
关键词：
Breast cancer; Cytology; Cell block; gene; DISH;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：917 / 921
页数：4
相关论文
共 50 条
  • [31] Her2/neu Testing in Breast Cancer: Comparative Analysis of In Situ Hybridization and Immunohistochemistry in a Dual-Testing System
    Solomon, James
    Fadare, Oluwole
    Hasteh, Farnaz
    MODERN PATHOLOGY, 2016, 29 : 505A - 505A
  • [32] Correlation of In Situ HER2 RNA Expression With HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Categories in Breast Cancer
    Tseng, Yu-Fen
    Li, Yu-Chia
    Lee, Yi-Hsuan
    Hu, Hsiang-We
    Zhang, Man-San
    Hung, Tze-Chun
    Lien, Huang-Chun
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (03) : e48 - e56
  • [33] Invasive breast cancer clinical outcome is predicted by a novel bright-field assay for the simultaneous detection of HER2 gene amplification and protein expression (SILVERFISH).
    Hicks, D
    Skacel, M
    Downs-Kelly, E
    Cheang, M
    Pettay, J
    Nielsen, T
    Huntsman, D
    Powell, R
    Hainfeld, J
    Grogan, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 43S - 43S
  • [34] Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer
    Horii, Rie
    Matsuura, Masaaki
    Iwase, Takuji
    Ito, Yoshinori
    Akiyama, Futoshi
    BREAST CANCER, 2014, 21 (05) : 598 - 604
  • [35] Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment
    Kosa, Csaba
    Kardos, Laszlo
    Kovacs, Judit
    Szollosi, Zoltan
    PATHOLOGY RESEARCH AND PRACTICE, 2013, 209 (03) : 147 - 150
  • [36] Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer
    Rie Horii
    Masaaki Matsuura
    Takuji Iwase
    Yoshinori Ito
    Futoshi Akiyama
    Breast Cancer, 2014, 21 : 598 - 604
  • [37] Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method
    Eiji Higaki
    Takeshi Kuwata
    Akiko Kawano Nagatsuma
    Yasunori Nishida
    Takahiro Kinoshita
    Masaki Aizawa
    Hiroaki Nitta
    Masato Nagino
    Atsushi Ochiai
    Gastric Cancer, 2016, 19 : 63 - 73
  • [38] Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method
    Higaki, Eiji
    Kuwata, Takeshi
    Nagatsuma, Akiko Kawano
    Nishida, Yasunori
    Kinoshita, Takahiro
    Aizawa, Masaki
    Nitta, Hiroaki
    Nagino, Masato
    Ochiai, Atsushi
    GASTRIC CANCER, 2016, 19 (01) : 63 - 73
  • [39] Neoadjuvant Treatment in Breast Cancer; Relationship to HER2 status including HER2 Copy Number using Brightfield Dual in situ Hybridization
    Neville, Grace
    O'Connell, Fionnuala
    Bennett, Michael
    Feeley, Linda
    O'Reilly, Seamus
    Browne, Tara Jane
    MODERN PATHOLOGY, 2018, 31 : 95 - 95
  • [40] Neoadjuvant Treatment in Breast Cancer; Relationship to HER2 status including HER2 Copy Number using Brightfield Dual in situ Hybridization
    Neville, Grace
    O'Connell, Fionnuala
    Bennett, Michael
    Feeley, Linda
    O'Reilly, Seamus
    Browne, Tara Jane
    LABORATORY INVESTIGATION, 2018, 98 : 95 - 95
12345